Stockreport

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology...

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF -- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks ---- Sequential enrollment planned for OPTIC thir [Read more]